Evidence map›Paper›PMID 41160117›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2026

Phytochemical characterization and multi-target mechanism of Gleditsia sinensis Fructus in lung adenocarcinoma treatment.

Zhengyuan Fan, Di Han, Tingting Shen, Ya Li, Suxiao Liu, Suyun Li

Abstract read
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Zhengyuan FanChinese Medicine Pharmacology (Respiratory) Laboratory, Henan Key Laboratory of Chinese Medicine for Respiratory Disease, the First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, 450008, China.
Di HanChinese Medicine Pharmacology (Respiratory) Laboratory, Henan Key Laboratory of Chinese Medicine for Respiratory Disease, the First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, 450008, China.
Tingting ShenChinese Medicine Pharmacology (Respiratory) Laboratory, Henan Key Laboratory of Chinese Medicine for Respiratory Disease, the First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, 450008, China.
Ya LiChinese Medicine Pharmacology (Respiratory) Laboratory, Henan Key Laboratory of Chinese Medicine for Respiratory Disease, the First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, 450008, China.
Suxiao LiuChinese Medicine Pharmacology (Respiratory) Laboratory, Henan Key Laboratory of Chinese Medicine for Respiratory Disease, the First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, 450008, China.
Suyun LiDepartment of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Henan University of Chinese Medicine, No.19 Renmin Road, Zhengzhou, 450000, Henan, China. suyunli@hactcm.edu.cn.ORCID http://orcid.org/0000-0003-1634-7992

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gleditsia sinensis Fructus (GSF) exhibits anti-cancer activity and is effective against lung adenocarcinoma (LUAD). However, its underlying mechanisms remain unclear. In this study, the potential chemical components, targets, and pathways of GSF in treating LUAD were investigated using UHPLC-HRMS combined with network pharmacology analysis. These findings were subsequently verified via molecular docking, molecular dynamics simulation, and in vitro cell experiments. The results showed that a total of 61 components targeting 192 LUAD-related genes were identified, and 177 candidate targets of GSF against LUAD were obtained, among which AKT1, SRC, EGFR, IL6, and TNF may be the core targets. Enrichment analysis revealed that the mechanisms were related to various cancer-related pathways, particularly the PI3K-AKT signaling pathway. Molecular docking demonstrated that the active components of GSF, particularly luteolin, exhibited excellent binding affinity to the top five core targets. Molecular dynamics simulation results showed a similar trend. Therefore, we identified luteolin as the primary active component of GSF. The cell experiments revealed that luteolin significantly inhibited cell growth and proliferation and promoted the apoptosis of A549 cells, exhibiting effects similar to those of cisplatin. In addition, luteolin significantly upregulated the expression of Bax and cleaved-caspase3 and decreased the expression of P-AKT and BCL2. Our results demonstrate that GSF can exert anti-LUAD effects through multi-components, multi-targets, and multi-pathways. Luteolin, one of the main active components of GSF, suppressed proliferation and induced apoptosis in A549 cells, possibly through inhibiting the AKT signaling pathway.

Indexed as

Adenocarcinoma of LungAntineoplastic Agents, PhytogenicDrugs, Chinese HerbalGleditsiaLung NeoplasmsPhytochemicalsA549 CellsApoptosisCell Line, TumorCell ProliferationFruitHumansMolecular Docking SimulationMolecular Dynamics SimulationNetwork PharmacologyProto-Oncogene Proteins c-aktAntineoplastic Agents, PhytogenicDrugs, Chinese HerbalPhytochemicalsProto-Oncogene Proteins c-aktA549Lung cancerLuteolinMolecular dockingMolecular dynamics simulationNetwork pharmacology

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.